Tharimmune Inc. (NASDAQ: THAR)
$4.23
+0.1600 ( +3.93% ) 34.9K
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Market Data
Open
$4.23
Previous close
$4.07
Volume
34.9K
Market cap
$3.39M
Day range
$3.97 - $4.34
52 week range
$2.75 - $142.50
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-k | Annual reports | 68 | Feb 23, 2024 |
8-k | 8K-related | 14 | Feb 08, 2024 |
4 | Insider transactions | 1 | Dec 18, 2023 |
8-k | 8K-related | 12 | Dec 12, 2023 |
8-k/a | 8K-related | 12 | Dec 11, 2023 |
8-k | 8K-related | 12 | Dec 08, 2023 |
8-k | 8K-related | 35 | Dec 07, 2023 |
4 | Insider transactions | 1 | Dec 04, 2023 |
8-k | 8K-related | 15 | Nov 27, 2023 |
8-k | 8K-related | 16 | Nov 17, 2023 |